Human CD27 Antibody Family

Varlilumab biosimilar isotypes: IgG1, IgG1fut, and IgG1NQ

Human monoclonal antibody (mAb) isotypes against human CD27

InvivoGen provides a family of anti-hCD27-derived monoclonal antibodies (mAbs) in multiple human isotypes.

They feature:

  • the variable region of varlilumab targeting the human cluster of differentiation 27 (hCD27)
  • a constant region that mediates different effector functions depending on the isotype.

The effector functions of the human isotypes in this family include antibody‑dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). You may choose between:

— IgG1 for high effector functions
     (Anti-hCD27-hIgG1 is the biosimilar of the clinical antibody varlilumab),

— IgG1fut for even higher effector functions
     (engineered non-fucosylated (fut) constant region), or

— IgG1NQ for no effector functions
     (engineered N-glycosylation mutated constant region).

InvivoGen's mAbs have been generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography.

READ MORE MARKER

Key features of the Anti-hCD27 isotype family

  • Clinically-relevant variable region targeting human CD27 (varlilumab)
  • Choice of different constant regions for high/low effector functions
  • Functionally validated by flow cytometry and ELISA
  • The absence of bacterial contamination has been confirmed

 

Varlilumab is a fully human agonist anti-CD27-hIgG1 mAb that activates the costimulatory molecule CD27 [1]. This receptor is constitutively expressed on the majority of mature T cells. In the appropriate context of T cell receptor engagement, the interaction of CD27 with its ligand CD70 (also known as CD27L) promotes T cell activation, maturation of effector capacity, and T cell memory [1-2]. This interaction became of interest to immunologists as a co-stimulatory immune checkpoint (IC) molecule and is the target of an anti-cancer drug in clinical trials [2].

 

References:

1. Vitale LA, et al.,2012. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res.;18(14):3812-21.
2. Sanborn RE, et al., 2022 Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer.;10(8):e005147.